Sertoli Cell-Treated Umbilical Cord Blood for Stroke

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R41NS046878-01
Agency Tracking Number: NS046878
Amount: $133,060.00
Phase: Phase I
Program: STTR
Awards Year: 2003
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Saneron Ccel Therapeutics, Inc.
13101 TELECOM DR, STE 105, USF, CENTER FOR ENTREPRENEURSHIP, Tampa, FL, 33637
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 DON CAMERON
 (813) 974-9431
 DCAMERON@HSC.USF.EDU
Business Contact
 NICOLE KUZMIN-NICHOLS
Phone: (813) 866-6370
Email: nkn@saneron-ccel.com
Research Institution
 UNIVERSITY OF SOUTH FLORIDA
 4202 E FOWLER AVE
TAMPA, FL, 33620
 Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): With the recent observations that stem-like cells outside the central nervous system (CNS) can differentiate into neurons, it is no longer inconceivable to suggest that stem cells derived from human umbilical cord blood (hUCB) could be used for cellular transplant therapy for neurological disorders, such as stroke. However, the greatest confounds of cell transplant therapy include rejection by the recipient (graft vs. host disease), and viability of the stem cells following cryopreservation. We have shown previously that SCs provide long-term localized immunosuppression and growth enhancement of transplanted cells and tissues. SCs provide a cocktail of trophic and immune protective factors that may be chronically present after transplantation. This Phase I research program proposes a series of well-controlled experiments using cell culture techniques to determine the most efficacious protocol for enhancing viability, neural differentiation, and cryopreservation of SC-treated hUCBs, which will be termed SCT-441, prior to their transplantation in an animal model of stroke. The optimal dose of SCT.441 will also be determined based on behavioral recovery. The success of directing and protecting stem cells obtained from umbilical cord blood into a neural phenotype (i.e. SCT-441) has important implications for the treatment of stroke in humans.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government